Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002100119-26-001518
Filing Date
2026-07-31
Accepted
2026-07-31 10:51:09
Documents
1
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5719
  Complete submission text file 0002100119-26-001518.txt   7564
Mailing Address 101 FEDERAL STREET BOSTON MA 02110
Business Address 101 FEDERAL STREET BOSTON MA 02110 (888) 958-1253
ZEVRA THERAPEUTICS, INC. (Subject) CIK: 0001434647 (see all company filings)

EIN.: 205894398 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-88808 | Film No.: 261226346
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 100 VANGUARD BLVD MALVERN PA 19355
Business Address 100 VANGUARD BLVD MALVERN PA 19355 610-669-6148
VANGUARD CAPITAL MANAGEMENT LLC (Filed by) CIK: 0002100119 (see all company filings)

EIN.: 392877419 | State of Incorp.: PA | Fiscal Year End: 1231
LEI: 529900ZEWTRLEJ6XE960
Type: SCHEDULE 13G